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Abstract
Aims/hypothesis Both energy restriction (ER) per se and
weight loss improve glucose metabolism in obese insulin-
treated type 2 diabetic patients. Short-term ER decreases
basal endogenous glucose production (EGP) but not glucose
disposal. In contrast the blood glucose-lowering mechanism
of long-term ER with substantial weight loss has not been
fully elucidated. The aim of this study was to investigate the
effect of loss of 50% of excess weight [50% excess weight
reduction (EWR)] on EGP, whole-body insulin sensitivity
and the disturbed myocellular insulin-signalling pathway in
ten obese insulin-treated type 2 diabetic patients.
Methods A euglycaemic–hyperinsulinaemic clamp with sta-
ble isotopes ([6,6-2H2]glucose and [
2H5]glycerol) combined
with skeletal muscle biopsies was performed during a very
low energy diet (VLED; 1,883 kJ/day) on day 2 and again
after 50% EWR. Oral blood glucose-lowering agents and
insulin were discontinued 3 weeks prior to the VLED and at
the start of the VLED, respectively.
Results Loss of 50% EWR (20.3±2.2 kg from day 2 to day
of 50% EWR) normalised basal EGP and improved insulin
sensitivity, especially insulin-stimulated glucose disposal
(18.8±2.0 to 39.1±2.8 μmol kg fat-free mass−1 min−1,
p=0.001). The latter was accompanied by improved insulin
signalling at the level of the recently discovered protein
kinase B/Akt substrates AS160 and PRAS40 along with a
decrease in intramyocellular lipid (IMCL) content.
Conclusions/interpretation Considerable weight loss in
obese, insulin-treated type 2 diabetic patients normalises
basal EGP and improves insulin sensitivity resulting from
an improvement in insulin signal transduction in skeletal
muscle. The decrease in IMCL might contribute to this
effect.
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Abbreviations
AS160 Akt substrate of 160 kDa
ER energy restriction
EGP endogenous glucose production
EWR excess weight reduction
FAT/CD36 fatty acid transporter
(homologue to human CD36)
FFM fat-free mass
FM fat mass
HIR hepatic insulin resistance index
IMCL intramyocellular lipid
MCRI metabolic clearance rate of insulin
PI3K phosphatidylinositol 3’-kinase
PKB/Akt protein kinase B/Akt
PRAS40 proline-rich Akt substrate of 40 kDa
Ra rate of appearance
Rd rate of disappearance
VLED very low energy diet
Introduction
Insulin resistance is of pivotal clinical importance in obese
patients with type 2 diabetes mellitus. Because more than 70%
of insulin-stimulated glucose transport occurs in skeletal
muscle [1], skeletal muscle insulin resistance contributes
substantially to the metabolic derangements seen in these
patients.
In type 2 diabetic patients the impairment in insulin-
stimulated glucose disposal is due to defects in the insulin-
signalling pathway regulating the translocation of GLUT-4 to
the cell membrane. Notably, defects in insulin-induced
phosphorylation of IRS-1 and phosphatidylinositol 3-kinase
(PI3K) [2–4] and in translocation of GLUT-4 to the cell
membrane [5, 6] have been found in skeletal muscle of
patients with type 2 diabetes, whereas, in contrast, total
GLUT-4 protein and mRNA levels have repeatedly been
shown to be normal [7, 8]. The involvement of the PI3K
substrate protein kinase B/Akt (PKB/Akt) in skeletal muscle
insulin resistance is less clear, illustrated by studies reporting
either normal [3, 9] or impaired activation [10, 11] by insulin.
However, the recently characterised Akt substrate 160
(AS160) [12, 13] has been implicated in the link between
PKB/Akt activation and GLUT-4 trafficking [14]; also,
insulin-mediated AS160 phosphorylation is impaired in
skeletal muscle of type 2 diabetic patients [15]. Collectively
these studies highlight the importance of the PI3K–PKB/Akt–
AS160-signalling pathway regulating GLUT-4 trafficking.
Energy restriction (ER) and weight loss both improve
hyperglycaemia in type 2 diabetic patients. We previously
reported that a 2 day very low energy diet [VLED, 1,883 kJ
(450 kcal)/day] decreased basal endogenous glucose pro-
duction (EGP) in obese insulin-treated type 2 diabetic
patients in whom all blood glucose-lowering medication
was discontinued [16]. These changes were accompanied
neither by an improvement in whole-body peripheral
insulin sensitivity nor by changes in insulin signalling, fuel
transporter [GLUT-4 and fatty acid transporter homologue
to human CD36 (FAT/CD 36)] content and localisation and
triacylglycerol content in skeletal muscle [17].
In the present study, we assessed whether a prolonged
VLED in obese insulin-treated type 2 diabetic patients
leading to substantial weight loss (50% of excess weight)
has a different blood glucose-lowering mechanism com-
pared with ER alone (2 day VLED).
Methods
Patients Ten obese patients with type 2 diabetes mellitus
(duration 8±3 years), eight women and two men (see patient
characteristics in Table 1) participated in this study, which
was approved by the Medical Ethical Committee of Leiden
University Medical Centre, after giving written informed
consent.
Patients had to use at least 30 U insulin/day (mean 94±
14 U/day; eight patients also used metformin and two patients
used rosiglitazone with the insulin therapy) and had to have a
BMI>30 kg/m2. In addition, patients had to have remaining
endogenous insulin secretion defined as a fasting plasma C-
peptide level >0.27 nmol/l or a twofold increase of the basal
C-peptide level after administration of 1 mg glucagon i.v.
Patients also had to have stable bodyweight for at least
3 months and were instructed not to alter lifestyle habits
from screening until the start of the study.
Diet and protocol outline Three weeks before the start of
the study, all oral blood glucose-lowering medication was
discontinued. At day −1 only short-acting insulin was
given, whereas evening doses of intermediate- and long-
acting insulin were omitted. On day 0, patients started a
VLED (1,883 kJ/day) consisting of three sachets of
Modifast (Nutrition & Santé, Antwerp, Belgium) per day,
providing about 50 g protein, 50–60 g carbohydrate, 7–9 g
lipid and 10 g dietary fibre. Insulin therapy remained
stopped from the start of the VLED onwards. After 48 h of
the VLED, patients were admitted to the research centre for
the metabolic studies (day 2) as outlined below. After this
study day patients continued the VLED until they had lost
50% of their excess weight (see Results), then the second
study day took place (day of 50% excess weight reduction,
EWR) (Fig. 1).
During the VLED patients visited the research centre
weekly for support to keep up with their diet, confirmation
of compliance and measurement of bodyweight, WHR,
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blood pressure and blood glucose regulation. No blood
glucose-lowering agents were used during this period.
Assessments of body composition On both study days, body
fat mass (FM) and fat-free mass (FFM) were measured by
bioelectrical impedance analysis (Bodystat 1500; Bodystat,
Douglas, Isle of Man, UK).
Length (m) and weight (kg), BMI and waist circumfer-
ence were measured according to WHO recommendations.
Metabolic studies Metabolic studies were performed as
described previously [17]. In short, basal rates of glucose
and glycerol turnover were assessed after 3 h of an adjusted
primed [17.6 μmol/kg × actual plasma glucose concentra-
tion (mmol/l)/5 (normal plasma glucose)] continuous
(0.33 μmol kg−1 min−1) infusion of [6,6-2H2]glucose
(enrichment 99.9%; Cambridge Isotopes, Cambridge, MA,
USA) and 1.5 h of a primed (1.6 μmol/kg) continuous
(0.11 μmol kg−1 min−1) infusion of [2H5]glycerol (Cambridge
Isotopes). Subsequently, insulin-stimulated rates of glucose
and glycerol turnover were measured after 4.5 h of a
hyperinsulinaemic–euglycaemic clamp (Actrapid; Novo
Nordisk Pharma, Alphen aan de Rijn, the Netherlands; rate
40 mU m−2 min−1). Glucose values were clamped at
5 mmol/l via the infusion of a variable rate of 20% glucose
enriched with 3% [6,6-2H2]glucose.
Basal and insulin-stimulated glucose and lipid oxidation
rates [18] were determined by indirect calorimetry with a
ventilated hood (Oxycon Beta; Mijnhardt Jaegher, Breda, the
Netherlands).
Blood chemistry Serum insulin was measured with an
immunoradiometric assay (Biosource, Nivelles, Belgium).
Serum C-peptide and glucagon levels were measured with an
RIA from Linco Research (St Charles, MO, USA). Growth
hormone was measured with a time-resolved immunofluo-
rescent assay (Wallac, Turku, Finland) specific for the
22 kDa growth hormone. Cortisol was measured with an
RIA (Sorin Biomedica, Milan, Italy). Serum triacylglycerol
was measured with a fully automated Modular P 800 and





Only short-acting insulin was given, last dose at evening meal 














Continue VLED until 50% of excess weight is lost
No blood glucose-lowering medication
Fig. 1 Protocol outline. See text
for explanation
Table 1 Patient characteristics and body composition parameters before and after 2 days of a VLED and again at 50% EWR with the VLED
Before VLED Day 2 VLED 50% EWR
Age (years) 55±3 – –
BMI (kg/m2) 40.2±1.6 39.7±1.7b 32.3±1.2d
Weight (kg) 113.0±7.1 110.9±6.9c 90.6±0.5d
FM (kg) 51.0±3.9 50.1±3.7 32.7±3.0d
Waist circumference (cm) 126.8±3.3 126.2±3.5 107.7±3.3d
Fasting plasma glucose (mmol/l) 11.1±0.8 12.5±0.5 7.8±0.5d
Fructosamine (nmol/l) (HbA1c 7.7±0.4%) 329±11 283±12
e
Fasting serum insulin (pmol/l) –a 168±2.2 106± 9f
Units of insulin (U/day) 94±14 0 0
Data are means±SEM
aValues likely to be unreliable because patients had used short-acting insulin therapy until the evening before
b p=0.049, c p=0.0001 day 2 compared with day 0
d p=0.0001 compared with both before VLED and day 2 VLED
e p=0.035, f p=0.001 day of 50% EWR compared with day 2 VLED
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Serum NEFAs were measured using the enzymatic
colorimetric acyl-CoA synthase/acyl-CoA oxidase assay
(Wako Chemicals, Neuss, Germany). Serum glucose and
[6,6-2H2]glucose as well as serum glycerol and [
2H5]
glycerol were determined in a single analytical run, using
GC-MS as described previously [19].
Muscle biopsies Muscle biopsies were taken from the vastus
lateralis muscle in the basal situation and 30 min after the start
of the insulin infusion [17, 20] using a modified Bergström
needle under localised anaesthesia with 1% lidocaine.
Muscle samples were snap-frozen in liquid nitrogen-cooled
isopentane and stored at −80°C until further analysis.
Insulin signalling Muscle biopsies were homogenised in
PI3K lysis buffer using an Ultraturrax mixer and centri-
fuged (15 min; 16,100×g; 4°C), then protein content was
determined using a BCA kit (Pierce, Rockford, IL, USA)
[21]. IRS-1 was immunoprecipitated overnight (4°C) from
1.5 mg protein using IRS-1 antibody K6, and PI3K activity
was determined as described previously [21].
In addition, proteins (25 μg per lane) were separated by
SDS-PAGE and blotted on polyvinylidene difluoride
membranes (Millipore, Bedford, MA, USA). Filters were
incubated overnight (4°C) with IRS-1 K6 and Akt-1
antibody (Upstate, Lake Placid, NY, USA), anti-phospho-
proline rich Akt substrate 40-Thr246 (#44-100G), anti-
phospho-AS160 (#44-1071G) (Biosource International,
Camarillo, CA, USA) and anti-AS160/TBC1D4 antibody
(Abcam, Cambridge, UK). Bound antibodies were detected
using appropriate horseradish peroxidase-conjugated sec-
ondary antibodies (Promega, Madison, WI, USA) at a
1:10,000 dilution, followed by visualisation by enhanced
chemiluminescence. Blots were quantified by densitometric
analysis of the films using Scion Image beta 4.02 software
(Scion, Frederick, MD, USA).
Oil Red O staining Tissue sections of basal biopsies
were stained with Oil Red O combined with a double-
immunofluorescence assay (anti-laminin and a monoclonal
antibody raised against adult human slow myosin heavy
chain) to allow quantification of intramyocellular lipids
(IMCLs) as described before [22].
Oil Red O epifluorescence signal was quantified for each
muscle cell of each cross section. Lipid droplet density was
calculated by dividing the total number of droplets by the
total IMCL area measured [22].
Western blotting for FAT/CD36 and GLUT-4 For Western
blotting analyses, muscle membrane fractions and total
muscle protein fractions were prepared as described before
for GLUT-4 [23] and fatty acid transporter homologue to
human CD36 (FAT/CD36) [17, 24] in biopsies taken during
the insulin-stimulated situation.
Blots were incubated with the polyclonal GLUT-4-BW
antibody [23] or the MO25 monoclonal antibody specific
for FAT/CD36 [24]. Protein bands were detected and
quantified with an Odyssey Infrared Imager (Li-Cor
Biosciences, Westburg BV, Leusden, The Netherlands).
Calculations A physiological and isotopic steady-state
was achieved during the last 30 min of the basal period
and the insulin-infusion period, therefore the rates of
appearance (Ra) and disappearance (Rd) for glucose and
glycerol were calculated as the tracer infusion rate divided
by the tracer-to-tracee ratio [25]. Glucose flux rates were
expressed per kg FFM, whereas glycerol flux rates were
normalised per kg FM.
EGP during the basal steady-state is equal to the Ra of
glucose, whereas EGP during the clamp was calculated as
the difference between Ra and the glucose infusion rate.
Since the fasting plasma insulin concentration is a strong
inhibitory stimulus for EGP, the basal hepatic insulin
resistance index (HIR) (μmol min−1 kgFFM
−1 pmol−1×l)
was calculated as the product of fasting EGP and fasting
plasma insulin concentration. Experimental validation for
the use of this index has been published [26, 27]. The
metabolic clearance rate of insulin (MCRI) was calculated
as the constant infusion rate of insulin divided by the
steady-state serum insulin concentration corrected for
endogenous insulin secretion [28].
Total lipid and carbohydrate oxidation rates were
calculated as described by Simonson and DeFronzo [18].
Non-oxidative glucose metabolism was calculated by
subtracting the glucose oxidation rate (determined by
indirect calorimetry) from glucose Rd.
Percentage excess weight was calculated as: 100×(weight/
ideal bodyweight)−100. Ideal bodyweight for height was
determined according to the 1983Metropolitan Life Insurance
tables (Metropolitan Life Insurance Company, New York,
USA).
Statistical analysis Data are presented as means±SEM.
Differences between day 2 and day of 50% EWR, as well as
differences between basal and insulin-stimulated biopsies
were analysed by the Student’s t test for paired samples. Non-
parametric (Wilcoxon signed-rank test) tests for paired
samples were performed when appropriate. Correlation
analysis was carried out using Pearson’s correlation. All
analyses were performed using SPSS for Windows version
12.0 (SPSS, Chicago, IL, USA). Significance was accepted
at p<0.05.
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Results
Weight and body composition Weight loss during the first
2 days (day 0 to day 2) was −2.1±0.3 kg. From day 2 until
the second study day, patients lost an additional 20.3±
2.2 kg (p=0.0001), 85% of which was FM (Table 1). BMI
decreased from 39.7±1.7 kg/m2 on day 2 to 32.3±
1.2 kg/m2 on the day of 50% EWR (p=0.0001). Mean
time to 50% EWR was 17 weeks (range 4–35 weeks). The
duration of time to 50% EWR was strongly and signifi-
cantly positively correlated with bodyweight and body FM
on day 0. There was no relationship between time to 50%
EWR and any measure of insulin sensitivity or change in
insulin sensitivity.
Fasting plasma glucose and insulin concentration Fasting
plasma glucose levels dropped significantly from day 2 to
day of 50% EWR (12.5±0.5 to 7.8±0.5 mmol/l, p=0.0001),
as did serum insulin concentrations (from 168±15 to 106±
9 pmol/l, p=0.001).
Serum fructosamine levels declined from 329±11 to 283±
12 nmol/l (p=0.035; Table 1).
EGP and whole-body glucose disposal On both study days,
plasma glucose was clamped at identical levels (5.1±0.3 and
5.4±0.3 mmol/l on day 2 and day of 50% EWR, respectively,
p=NS). The degree of exogenous hyperinsulinaemia was
lower on the day of 50% EWR (561±28 pmol/l) compared
with day 2 (626±23 pmol/l, p=0.023), despite equal insulin
infusion rates (40 mU m−2 min−1). This was the result of
the increased MCRI (Table 2).
Basal EGP decreased ∼20% from day 2 to the day of
50% EWR and insulin suppression of EGP also was
significantly stronger on the day of 50% EWR in absolute
terms. Consequently, the HIR was significantly lower on
the day of 50% EWR than on day 2 under both basal and
insulinised conditions (Table 2).
Of the hormones involved in the regulation of EGP,
fasting serum cortisol and glucagon concentrations did not
change with weight loss, whereas fasting growth hormone
levels increased as expected (Table 2).
Insulin-stimulated glucose disposal increased 107% from
day 2 to the day of 50% EWR. If we correct for the difference
in clamp serum insulin levels between study days by
dividing glucose Rd by the clamp serum insulin levels, the
difference in peripheral insulin sensitivity between study
days becomes even more significant (0.03 vs 0.07 μmol
min−1 kgFFM
−1 pmol−1×l, p=0.0001).
Glycerol Ra and NEFAs, glycerol and triacylglycerol Basal
glycerol Ra decreased by 35% between study days. Exoge-
nous insulin failed to suppress glycerol Ra on day 2 but did
so on the day of 50% EWR, to levels that were significantly
different from day 2 (Table 2). Accordingly, fasting levels of
Table 2 Metabolic parameters during a VLED on day 2 and at 50% EWR
Day 2 Day of 50% EWR
Basal Clamp p value Basal Clamp p value
Glucose Rd (μmol kgFFM
−1 min−1) 20.0±0.9 18.8±2.0 NS 16.4±1.2c 39.1±2.8c 0.001
Glucose Ox (μmol kgFFM
−1 min−1) 6.7±1.4 6.1±0.9 NS 4.2±0.4 12.7±1.5b 0.001
NOGD (μmol kgFFM
−1 min−1) 14.8±1.1 12.2±1.6 NS 12.4±1.1a 27.7±2.8b 0.005
EGP (μmol kgFFM
−1 min−1) 20.0±0.9 8.5±0.9 0.0001 16.4±1.2c 4.6±1.2b 0.0001
HIR (μmol kgFFM
−1 min−1 pmol−1×l) 3,319±245 5,251±500 0.005 1,729±193d 2,511±633c NS
Glycerol Ra (μmol kgFM
−1 min−1) 16.4±2.3 11.5±2.3 NS 14.6±1.4 7.5±1.6 0.012
Lipid Ox (μmol kgFFM
−1 min−1) 8.0±0.5 8.3±0.3 NS 7.1±0.5 5.5±0.8c 0.011
MCRI (ml m
−2 min−1) – 0.47±0.02 – – 0.53±0.03a –
Glucose (mmol/l) 12.5±0.5 5.1±0.3 0.0001 7.8±0.5d 5.4±0.3 0.003
Plasma insulin (pmol/l) 168±15 626±23 0.0001 106±9c 561±28a 0.0001
Glycerol (mmol/l) 150±15 114±18 NS 108±12c 65±12a 0.011
NEFA (mmol/l) 1.6±0.2 1.1±0.3 NS 1.2±0.1a 0.3±0.1a 0.012
Triacylglycerol (mmol/l) 2.7±0.5 2.5±0.5 NS 1.2±0.1c 0.9±0.1a 0.0001
Cortisol (nmol/l) 451±30 404±49 NS 419±34 232±31b 0.001
Glucagon (ng/l) 63.2±8.3 86.6±15.0 NS 70.7±5.1 38.9±2.7 0.001
Growth hormone (mU/l) 1.2±0.4 4.0±1.5 0.002 3.7±1.5 2.4±0.9 NS
Data are means±SEM
a p<0.05, b p<0.01, c p<0.001, d p<0.0001 for day 2 vs day of 50% EWR
To convert insulin from pmol/l to mU/l divide by 6.945
NOGD, non-oxidative glucose disposal; Ox, oxidation
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NEFAs, triacylglycerol and glycerol declined significantly,
and clamp values of serum NEFA and glycerol all declined
between study days both in the fasting state and in response
to euglycaemic hyperinsulinaemia, reflecting a better sup-
pressibility of lipolysis by insulin (Table 2).
Glucose and lipid oxidation rates On the day of 50%
EWR, insulin infusion increased the rate of glucose
oxidation significantly compared with day 2. Basal as well
as insulin-stimulated non-oxidative glucose disposal also
increased significantly after weight loss. The ability of
insulin to suppress lipid oxidation was improved with
weight loss (Table 2).
Insulin signalling in skeletal muscle biopsies Absolute
levels of insulin-stimulated IRS-1-associated PI3K were
not different between both study days but the increase over
basal was significant after weight loss because of lower
basal levels (p=0.01, Fig. 2a, Table 3). To corroborate this
finding, we also assessed the phosphorylation of two more
distal components of the insulin-signalling system, i.e. the
recently identified PKB/Akt substrates AS160 and proline-
rich Akt substrate 40 (PRAS40). Basal as well as insulin-
stimulated AS160 and PRAS40 phosphorylation, corrected
for protein content, were significantly higher after weight
loss compared with day 2 of the VLED (Fig. 2b,c and
Table 3). On the day of 50% EWR, insulin-stimulated
glucose disposal correlated significantly with absolute levels
of AS160, which is a well-defined intermediate in GLUT-4
translocation, as well as the difference between basal and
clamp (i.e. delta) AS160. The correlation with delta PI3K
just failed to reach significance (r=0.69, p=0.059).
Effect of weight loss on the fuel transporters GLUT-4 and
FAT/CD36 Weight reduction had no statistically significant
effect on the abundance of the fuel transporters GLUT-4
(Fig. 3) and FAT/CD36 (data not shown) at the plasma
membrane following hyperinsulinaemia despite the fact that
seven out of the ten patients showed a higher GLUT-4
density at the cell membrane after weight loss.
IMCL content as assessed with an Oil Red O staining Oil
red O staining showed a reduction in IMCL after weight loss,
in both type I and type II muscle fibres (Fig. 4). Type I muscle
fibres, stained with the antibody against human slow myosin
heavy chain, contained significantly more IMCL on either
study day compared with the unstained type II muscle fibres
(Fig. 5a). The percentage of type I fibres did not change with
weight loss (Fig. 5b). Interestingly, time to 50% EWR
correlated negatively with the number of type I fibres at the
start of the diet (day 2), r=−0.64, p=0.046. The amount of
IMCL correlated positively with lipid oxidation (r=0.74, p=
0.024) and negatively with whole-body insulin-stimulated
























































































Fig. 2 Representative immunoblots (upper sections) and quantifica-
tion [arbitrary units (AU), means±SEM] (lower sections) of IRS-1-
associated PI3K activity (a), AS160 phosphorylation (b) and PRAS40
phosphorylation (c) in vastus lateralis muscle biopsies obtained on
day 2 of a VLED and at 50% EWR in basal (black bars) and
hyperinsulinaemic–euglycaemic conditions (grey bars). Note that for
IRS-1-associated PI3K activity only insulin-stimulated increase over
basal is significant on the day of 50% EWR, whereas AS160
phosphorylation and PRAS40 phosphorylation both show absolute
increases in the basal and insulin-stimulated situation after weight
loss. *p<0.05, **p<0.01, ***p<0.001 clamp vs basal. †p<0.05 day
of 50% EWR compared with day 2, basal as well as insulin-stimulated
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glucose disposal (r=−0.63, p=0.049) on the day of 50%
EWR. On the other hand, the change in IMCL did not
correlate with change in bodyweight, glucose or lipid
metabolism, insulin signalling or FAT/CD36 content.
Discussion
Compared with short-term ER (2 day VLED), which only
affects basal EGP [16, 17], long-term ER leading to 50%
EWR reduced basal EGP and improved insulin sensitivity
of the liver, adipose tissue and skeletal muscle in obese,
insulin-treated type 2 diabetic patients. These effects
occurred despite the fact that patients had been taken off
all blood glucose-lowering medication (including insulin)
during the VLED and were still obese at the end of the
VLED (BMI=32.3 kg/m2).
Insulin-stimulated glucose disposal improved by ∼100%.
This is comparable with the improvements seen in obese non-
diabetic patients in whom restrictive bariatric surgery was
used to induce weight loss: an increase inM value from 7–19
to ∼35 μmol kgFFM−1 min−1 [29, 30] compared with the
increase (from 9.9±2.3 to 37.2±4.6 μmol kgFFM
−1 min−1)
seen in our patients. In skeletal muscle this increase in
insulin-stimulated glucose disposal was reflected in increased
insulin signalling at the level of two recently discovered
downstream components of PKB/AKT: AS160 and
PRAS40, whereas IRS-1-associated PI3K activity showed
no difference in absolute levels, although the increase over
basal was significant after weight loss. Insulin-stimulated
phosphorylation of AS160 is linked to GLUT-4 translocation
and has previously been reported to be disturbed in skeletal
muscle of moderately obese (BMI=27 kg/m2) type 2 diabetic
patients with relatively mild diabetes [15]. We did not study
control individuals and cannot therefore compare insulin-
stimulated AS160 phosphorylation in our patients with that
of healthy lean individuals. However, our patients were more
obese (BMI=40.2±1.6 kg/m2) and insulin-resistant than the
patients in the study mentioned above [15]. Nonetheless, we
found that insulin had a significant effect on AS160
phosphorylation on both study days and that weight
reduction enhances insulin-stimulated AS160 phosphoryla-
tion. To the best of our knowledge these findings have not
been described before.
The similar absolute levels of insulin-stimulated IRS-1-
associated PI3K activity after weight loss were unexpected in
light of the increase of the more distal signalling compo-
nents, and we have no good explanation for it. It might be,
although unlikely [20], that the timing of the biopsy was
such that levels were already declining while those of
PRAS40 and AS160 were still rising. Alternatively, there
might be no 1:1 relationship between PI3K and AS160 or
PRAS40, as was shown for activation of IRS-1 and PI3K
[2]. Furthermore, it might be that these were the maximal
possible insulin-stimulated PI3K values for this particular
patient group (obese type 2 diabetic patients with advanced
disease who were still obese at the end of the study), but we
did not study a dose–effect curve [4, 20]. Perhaps more
likely, given the fact that interventions with thiazolidine-
diones [31, 32] and exercise [33] also show discrepancies
between improvement of whole-body insulin-stimulated
glucose disposal and no effect on PI3K activation, is that
there is another activation route of PI3K–PKB/Akt–AS160.
Finally, the increase of insulin-stimulated PI3K activity over
basal could still have played a role. However, this is unclear
from our results and for now we have insufficient arguments
Table 3 Activity levels of measured insulin-signalling molecules
Day 2 Day of 50% EWR
Basal Clamp p value Basal Clamp p value
IRS-1-associated PI3K activity 21.7±3.3 28.9±3.0 NS 18.4±2.4 29.9±2.5 0.01
AS160 phosphorylation 15.4±1.7 27.1±2.0 0.008 23.6±2.6a 39.0±4.0a 0.02
PRAS40 phosphorylation 9.0±1.1 23.7±4.2 0.016 14.4±2.4b 52.9±5.4c 0.001
Data are means ± SEM
Data are corrected for protein expression levels and are expressed in arbitrary units (see Methods)























Fig. 3 Quantification of GLUT-4 (AU, arbitrary units) at the cell
membrane during insulin-stimulated conditions on day 2 of a VLED
and at 50% EWR. Data are means±SEM. Changes between study days
were not significant
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for a role of PI3K in the improvement of insulin-stimulated
glucose disposal.
Notably, we observed, also for the first time, that weight
reduction significantly increases insulin-stimulated PRAS40
phosphorylation, another substrate for PKB/Akt. PRAS40
has been identified as a component of the mammalian target
of rapamycin (mTOR) nutrient-sensing pathway, whose
activity is deregulated in rodent models of insulin resistance
[34, 35]. Although the physiological function of PRAS40 in
insulin action is not completely clear, we recently observed
that phosphorylation of this protein is induced by physio-
logical hyperinsulinaemia in insulin target tissues, and is
blunted under conditions of high fat diet-induced insulin
resistance [36]. Whether the improvement in insulin-
stimulated PRAS40 phosphorylation also relates to mTOR
and whether it can be ascribed to weight loss and/or ER
will be the subject of further studies.
Remarkably, the improvement in insulin signalling was
not accompanied by a significant improvement in GLUT-4
translocation to the cell membrane. Others have also
reported a dissociation between insulin-stimulated glucose
disposal and improvement in either insulin signalling and/
or GLUT-4 content at the cell membrane. Ryder et al. [5]
found that although insulin-stimulated glucose disposal was
50% lower in patients with type 2 diabetes compared with
lean control individuals, insulin-stimulated cell surface
GLUT-4 content over basal was only 10% that of healthy
controls. In another study, Karlsson et al. found a
significant, 36% improvement in insulin-stimulated whole-
body glucose uptake after 26 weeks of treatment with
rosiglitazone in newly diagnosed type 2 diabetic patients;
this change, however, was not accompanied by improved
signalling of IRS-1-associated PI3K, PKB/AKT or AS160
[32]. Finally, Friedman et al. [37] showed that loss of 36%
of initial bodyweight by gastric bypass surgery improved
whole-body glucose disposal threefold and maximal glu-
cose transport activity in vitro by 50% in three non-diabetic
and four type 2 diabetic morbidly obese individuals with no
effect on total GLUT-4 protein content in skeletal muscle
biopsies. Collectively, these findings indicate that it is not
Day 2 Day 50% EWR











































Fig. 5 a Quantification of the percentage IMCL in type I muscle
fibres (black bars), type II muscle fibres (grey bars) and mean per
cent IMCL (i.e. type I and II fibres combined, hatched bars) on
day 2 of a VLED and at 50% EWR. Note the significant decrease
in IMCL after weight loss in both fibre types. b The number of
type I (black bars) and type II (grey bars) fibres on either study day.
Note the significant increase in type I muscle fibres after weight loss.
***p<0.001, ****p<0.0001 day 2 vs day of 50% EWR. †p<0.0001
per cent IMCL in type I vs per cent IMCL in type 2 muscle fibres
Fig. 4 Oil Red O staining (red) in combination with myosin heavy
chain type 1 immunofluorescence (green) and laminin staining (blue)
in cryosections of vastus lateralis muscle on day 2 of a VLED (a) and
at 50% EWR (b). Note the decrease in intramyocellular triacylglycerol
content on the day of 50% EWR shown in Fig. 5b
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the amount of GLUT-4 at the cell membrane but its
function and, consequently, the velocity of glucose trans-
port across the membrane that is quantitatively responsible
for insulin-stimulated glucose disposal, as has been de-
scribed previously [38]. Alternatively, another glucose
transporter, either GLUT-1 [5] or a yet unidentified one,
may have contributed to the increase in glucose uptake seen
after weight loss. Another possible explanation is that
insulin-stimulated glucose disposal in adipose tissue is
greatly enhanced with weight loss.
It has been hypothesised that accumulation of IMCL
metabolites is involved in the impaired insulin signalling
via phosphorylation of IRS-1 and IRS-2 on serine residues,
thereby rendering these serine-phosphorylated IRSs unable
to associate with and activate PI3K [39]. In our study,
substantial weight loss was associated with a significant
decrease in IMCL, and the amount of IMCL on the day of
50% EWR correlated negatively with the glucose disposal
rate. Indeed, other studies also revealed a similar associa-
tion [30, 40]. Rather than triacylglycerol itself, derivatives
such as fatty acyl CoAs and diacylglycerol seem to be the
causal factor for the development of insulin resistance [39].
Moreover, there is a potential link between the accumula-
tion of these metabolites and the mitochondrial dysfunction
that has been observed in type 2 diabetic patients and their
offspring [39]. We did not measure mitochondrial density
or ATP production but one expects that after weight loss
due to ER, the organism has shifted to fatty acid beta-
oxidation rather than to glucose oxidation for muscle ATP
production. This may have led to lower fatty acid
concentrations in the sarcoplasma and thereby to improved
insulin sensitivity. Clearly FAT/CD36 does not seem to be
involved in the decrease in IMCL since sarcolemmal FAT/
CD36 content did not change with weight loss.
Patients with type 2 diabetes have a decreased percent-
age of type I (oxidative) muscle fibres and an increased
percentage of type IIb (glycolytic) muscle fibres [41, 42].
Weight loss did not result in a significant increase in the
percentage of type I muscle fibres in our study, which is
consistent with that of all [43–45] but one other study [46].
Interestingly, like one other study [47], we also found a
negative relationship between the amount of type I muscle
fibres on day 2 and time to 50% EWR.
Whether the withdrawal of high doses of insulin has also
played a role in the observed improvements in insulin
sensitivity of liver, adipose tissue and muscle cannot be
deduced from this study. In our short-term (2 day VLED)
study we found no arguments for this [16, 17]. A study by
Del Prato et al. shows that chronic (72–96 h) physiological
hyperinsulinaemia impairs insulin sensitivity of the pancreas
and muscle, not of the liver [48]. How long it takes to restore
normal insulin sensitivity after cessation of hyperinsulin-
aemia is unknown. When a VLED and instituting insulin
therapy were compared as therapy for type 2 diabetic
patients on oral drug failure, both improved glucose levels
but only a VLED improved insulin-stimulated glucose
disposal [49]. So, it may very well be that the high doses
of insulin used by our patients have contributed to their
insulin resistance and that the withdrawal of this insulin
played a role in the improvement in insulin sensitivity.
In conclusion, short-term energy restriction (2 day VLED)
improves hyperglycaemia primarily via a decrease in EGP
[16, 17]. Moderate weight reduction (approximately 8 kg)
also improves hepatic insulin sensitivity [50], and substan-
tial weight loss improves all aspects of glucose metabolism
(this study). To the best of our knowledge this is the first
study to show that weight loss improves insulin signal trans-
duction, especially insulin-stimulated AS160 and PRAS40
phosphorylation. The large increase in insulin sensitivity in
patients who were still obese and used no glucose-lowering
medication again stresses the importance of weight-reducing
approaches in the treatment of obese type 2 diabetic patients.
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